The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zaidieva Ya.Z.

Moscow Regional Research Institute of Obstetrics and Gynecology

Balan V.E.

Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

Tsar’kova A.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Relationship between adipocytes and androgens — the cause of comorbidities in women with polycystic ovary syndrome

Authors:

Zaidieva Ya.Z., Balan V.E., Tsar’kova A.V.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2023;23(6): 25‑33

DOI: 10.17116/rosakush20232306125

Read: 1866 times

Download PDF (RU)
Contact the author
Table of contents

RELATIONSHIP BETWEEN ADIPOCYTES AND ANDROGENS — THE CAUSE OF COMORBIDITIES IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
RELATIONSHIP BETWEEN ADIPOCYTES AND ANDROGENS — THE CAUSE OF COMORBIDITIES IN WOMEN WITH POLYCYSTIC OVARY SYNDROME

To cite this article:

Zaidieva YaZ, Balan VE, Tsar’kova AV. Relationship between adipocytes and androgens — the cause of comorbidities in women with polycystic ovary syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2023;23(6):25‑33. (In Russ.)
https://doi.org/10.17116/rosakush20232306125

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Modern aspe­cts of gestational diabetes mellitus: defi­nition, risk factors. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):35-41
«Metabolic health» and endo­thelial function in women with poly­cystic ovary syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):27-34
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Triglycerides-Glucose Index as an inte­gral biomarker of insu­lin resi­stance and cardiovascular diseases. Russian Journal of Preventive Medi­cine. 2025;(5):124-129
Drinking mine­ral water for progressive resi­stance to insu­lin. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):24-30
Pharmacotherapy of the meta­bolically asso­ciated fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(10):103-108
Rela­tionship of glycemic, meta­bolic, immuno-inflammatory, and psychopathological para­meters in patients with depressive diso­rder: a retrospective analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):223-227
The role of the human gut microbiota in the phenotypic age dete­rmination. Russian Journal of Preventive Medi­cine. 2026;(1):74-80
Asso­ciation of triglyceride-glucose index and sleep dura­tion in people aged 25—44 years old. Russian Journal of Preventive Medi­cine. 2026;(1):94-101
Abstract:

The review presents the current knowledge about the relationship between androgens and adipocytes in women with polycystic ovary syndrome. Adipocytes are actively involved in steroid metabolism. The conversion of «weak» androgens to «strong» androgens takes place in them. In addition, adipocytes modulate ovarian production of testosterone and androstenedione through the action of various adipocytokines. Androgens also participate in the proliferation and differentiation of adipocytes, stimulate the secretion of adipocytokines and promote the accumulation of visceral adipose tissue. Androgens cause hypertrophy of adipocytes and contribute to the formation of insulin resistance in these cells. Androgens are known to increase insulin secretion by β-cells. Insulin, in turn, affects ovarian theca cells, leading to increased secretion of androgens. The described pathophysiological mechanisms contribute to the development of associated diseases and pathological conditions such as dyslipidemia, chronic inflammation of low intensity, non-alcoholic fatty liver disease, metabolic syndrome, type 2 diabetes mellitus, arterial hypertension and other cardiovascular diseases.

Keywords:

polycystic ovaries
hyperandrogenism
adipocytes
insulin resistance

Authors:

Zaidieva Ya.Z.

Moscow Regional Research Institute of Obstetrics and Gynecology

Balan V.E.

Moscow Regional Scientific Research Institute of Obstetrics and Gynecology

Tsar’kova A.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Received:

24.11.2022

Accepted:

20.12.2022

Close metadata

References:

  1. Schiffer L, Arlt W, O’Reilly MW. Understanding the role of androgen action in female adipose tissue. Front Horm Res. 2019;53:33-49. 
  2. Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020;35:100937.
  3. Spritzer PM, Ramos RB, Marchesan LB, de Oliveira M, Carmina E. Metabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021;13:18. 
  4. De Ugarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454-1460.
  5. Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril. 2010;93:1938-1941.
  6. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2013;14:95-109. 
  7. de Medeiros SF, Yamamoto MMW, Souto de Medeiros MA, Barbosa BB, Soares JM, Baracat EC. Changes in clinical and biochemical characteristics of polycystic ovary syndrome with advancing age. Endocr Connect. 2020;9:74-89. 
  8. Dumesic DA, Akopians AL, Madrigal VK, Ramirez E, Margolis DJ, Sarma MK, Thomas AM, Grogan TR, Haykal R, Schooler TA, Okeya BL, Abbott DH, Chazenbalk GD. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 2016;101:11:4178-4188.
  9. McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab. 2011;96:E1756-1760.
  10. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000;11:327-332. 
  11. Li J, Papadopoulos V, Vihma V. Steroid biosynthesis in adipose tissue. Steroids. 2015;103:89—104. 
  12. Lerchbaum E, Schwetz V, Rabe T, Giuliani A, Obermayer-Pietsch B. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype. PLoS One. 2014;9:e108263.
  13. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab. 1985;61:564-570. 
  14. McCartney CR, Prendergast KA, Chhabra S, Eagleson CA, Yoo R, Chang RJ, Foster CM, Marshall JC. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab. 2006;91:5:1714-1722.
  15. Di Nisio A, Sabovic I, De Toni L, Rocca MS, Dall’Acqua S, Azzena B, De Rocco Ponce M, Foresta C. Testosterone is sequestered in dysfunctional adipose tissue, modifying androgen-responsive genes. Int J Obes (Lond). 2020;44:7:1617-1625.
  16. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S. Expression cloning and characterization of human 17 betahydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J Biol Chem. 1993;268:12964-12969.
  17. Blouin K, Nadeau M, Mailloux J, Daris M, Lebel S, Luu-The V, Tchernof A. Pathways of adipose tissue androgen metabolism in women: Depot differences and modulation by adipogenesis. Am J Physiol Endocrinol Metab. 2009;296:E244-255. 
  18. Boulton KL, Hudson DU, Coppack SW, Frayn KN. Steroid hormone interconversions in human adipose tissue in vivo. Metabolism. 1992;41:556-559. 
  19. Fouad Mansour M, Pelletier M, Boulet MM, Mayrand D, Brochu G, Lebel S, Poirier D, Fradette J, Cianflone K, Luu-The V, Tchernof A. Oxidative activity of 17beta-hydroxysteroid dehydrogenase on testosterone in male abdominal adipose tissues and cellular localization of 17beta-HSD type 2. Mol Cell Endocrinol. 2015;414: 168-176. 
  20. Blouin K, Nadeau M, Perreault M, Veilleux A, Drolet R, Marceau P, Mailloux J, Luu-The V, Tchernof A. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clin Endocrinol (Oxf). 2010;72:176-188. 
  21. Chazenbalk G, Singh P, Irge D, Shah A, Abbott DH, Dumesic DA. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013;78: 920-926. 
  22. Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol. 2008;108:272-280. 
  23. Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol. 2004;183:331-342. 
  24. Quinkler M, Bujalska IJ, Tomlinson JW, Smith DM, Stewart PM. Depot-specific prostaglandin synthesis in human adipose tissue: A novel possible mechanism of adipogenesis. Gene. 2006;380: 137-143. 
  25. Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, Nightingale P, Tomlinson JW, Arlt W, Stewart PM. Increased 5 alphareductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:9:3558-3566.
  26. Blouin K, Nadeau M, Perreault M, Veilleux A, Drolet R, Marceau P, Mailloux J, Luu-The V, Tchernof A. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clin Endocrinol (Oxf). 2010;72:176-188. 
  27. Wang L, Li S, Zhao A, Tao T, Mao X, Zhang P, LiuW. The expression of sex steroid synthesis and inactivation enzymes in subcutaneous adipose tissue of PCOS patients. J Steroid Biochem Mol Biol. 2012;132:120-126. 
  28. de Medeiros SF, de Medeiros MAS, Barbosa BB, Yamamoto MMW. Relationship of biological markers of body fat distribution and corticosteroidogenic enzyme activities in women with polycystic ovary syndrome. Horm Metab Res. 2019;51:639-648. 
  29. de Medeiros SF, Angelo LCA, Souto de Medeiros MA, Barbosa BB, Yamamoto MMW. Exploring the activity of the enzyme 11β-hydroxylase in the polycystic ovary syndrome. Horm Mol Biol Clin Investig. 2020;41:2. 
  30. de Medeiros SF, Rodgers RJ, Norman RJ. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome. Hum Reprod Update. 2021;27:771-796. 
  31. Biason-Lauber A, Zachmann M, Schoenle EJ. Effect of leptin on CYP17 enzymatic activities in human adrenal cells: new insight in the onset of adrenarche. Endocrinology. 2000;141:1446-1454.
  32. Rossi GP, Sticchi D, Giuliani L, Bernante P, Zavattiero S, Pessina AC, Nussdorfer GG. Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. Int J Mol Med. 2006;17:6:975-980. 
  33. Chapman IM, Wittert GA, Norman RJ. Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters. Clin Endocrinol (Oxf). 1997;46:175-181. 
  34. Sieminska L, Marek B, Kos-Kudla B, Niedziolka D, Kajdaniuk D, Nowak M, Glogowska-Szelag J. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest. 2004;27:6:528-534. 
  35. Raeisi T, Rezaie H, Darand M, Taheri A, Garousi N, Razi B, Roever L, Mohseni R, Hussien Mohammed S, Alizadeh S. Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: asystematic review and meta-analysis. PLoS One. 2021;16:3:e0246200.
  36. Weiping L, Qingfeng C, Shikun M, Xiurong L, Hua Q, Xiaoshu B, Suhua Z, Qifu L. Elevated serum RBP4 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine. 2006;30:3:283-287. 
  37. Ademoglu E, Berberoglu Z, Carlioglu A, Dellal F, Gorar S, Alphan Z, Uysal S, Karakurt F. Higher levels of circulating chemerin in both lean and obese patients with polycystic ovary syndrome. Minerva Ginecol. 2014;66:6:535-542. 
  38. Boulton KL, Hudson DU, Coppack SW, Frayn KN. Steroid hormone interconversions in human adipose tissue in vivo. Metabolism. 1992;41:556-559. 
  39. Dieudonne MN, Pecquery R, Boumediene A, Leneveu MC, Giudicelli Y. Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. Am J Physiol. 1998;274:C1645-1652.
  40. González F, Nair KS, Daniels JK, Basal E, Schimke JM. Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. Am J Physiol Endocrinol Metab. 2012;302:E297-306. 
  41. Crisosto N, Flores C, Maliqueo M, Echiburú B, Vásquez J, Maluenda F, Sir-Petermann T. Testosterone increases CCL-2 expression in visceral adipose tissue from obese women of reproductive age. Mol Cell Endocrinol. 2017;444:59-66. 
  42. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002;23:175-200. 
  43. Xu XF, De Pergola G, Björntorp P. Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology. 1991;128:379-382. 
  44. Bolduc C, Yoshioka M, St-Amand J. Transcriptomic characterization of the long-term dihydrotestosterone effects in adipose tissue. Obesity (Silver Spring). 2007;15:1107-1132.
  45. Gupta V, Bhasin S, Guo W, Singh R, Miki R, Chauhan P, Choong K, Tchkonia T, Lebrasseur NK, Flanagan JN, Hamilton JA, Viereck JC, Narula NS, Kirkland JL, Jasuja R. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol. 2008;296:1-2:32-40. 
  46. Newell-Fugate AE. The role of sex steroids in white adipose tissue adipocyte function. Reproduction. 2017;153:R133-149. 
  47. De Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord. 2000;24(suppl 2):59-63. 
  48. Rice SP, Zhang L, Grennan-Jones F, Agarwal N, Lewis MD, Rees DA, Ludgate M. Dehydroepiandrosterone (DHEA) treatment in vitro inhibits adipogenesis in human omental but not subcutaneous adipose tissue. Mol Cell Endocrinol. 2010;320:1-2:51-57. 
  49. Hernandez-Morante JJ, Perez-de-Heredia F, Lujan JA, Zamora S, Garaulet M. Role of DHEA-S on body fat distribution: Gender- and depot-specific stimulation of adipose tissue lipolysis. Steroids. 2008;73:209-215. 
  50. Dimitriadis GK, Kyrou I, Randeva HS. Polycystic ovary syndrome as a proinflammatory state: the role of adipokines. Curr Pharm Des. 2016;22:5535-5546.
  51. O’Reilly MW, House PJ, Tomlinson JW. Understanding androgen action in adipose tissue. J Steroid Biochem Mol Biol. 2014;143:277-284. 
  52. Veilleux A, Caron-Jobin M, Noël S, Laberge PY, Tchernof A. Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women. Diabetes. 2011;60:1504-1511.
  53. Frühbeck G, Méndez-Giménez L, Fernández-Formoso JA, Fernández S, Rodríguez A. Regulation of adipocyte lipolysis. Nutr Res Rev. 2014;27:63-93. 
  54. Elbers JM, de Jong S, Teerlink T, Asscheman H, Seidell JC, Gooren LJ. Changes in fat cell size and in vitro lipolytic activity of abdominal and gluteal adipocytes after a one-year cross-sex hormone administration in transsexuals. Metabolism. 1999;48:1371-1377.
  55. White UA, Tchoukalova YD. Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta. 2014;1842: 377-392. 
  56. Varlamov O, Chu MP, McGee WK, Cameron JL, O’Rourke RW, Meyer KA, Bishop CV, Stouffer RL, Roberts CT Jr. Ovarian cycle-specific regulation of adipose tissue lipid storage by testosterone in female nonhuman primates. Endocrinology. 2013;154:11: 4126-4135.
  57. Douchi T, Ijuin H, Nakamura S, Oki T, Yamamoto S, Nagata Y. Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol. 1995;86:516-519. 
  58. Ek I, Arner P, Rydén M, Holm C, Thörne A, Hoffstedt J, Wahrenberg H. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes. 2002;51:2:484-492. 
  59. Liu F, He J, Wang H, Zhu D, Bi Y. Adipose morphology: a critical factor in regulation of human metabolic diseases and adipose tissue dysfunction. Obes Surg. 2020;30:5086-5100.
  60. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149:219-227. 
  61. Condorelli RA, Calogero AE, Di Mauro M, Mongioi’ LM, Cannarella R, Rosta G, La Vignera S. Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index. J Endocrinol Invest. 2018;41:4:383-388. 
  62. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep. 2011;11:179-184. 
  63. Tandon P, Wafer R, Minchin JEN. Adipose morphology and metabolic disease. J Exp Biol. 2018;221:jeb164970.
  64. Gregoire FM. Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Med (Maywood). 2001;226:997-1002.
  65. Echiburú B, Pérez-Bravo F, Galgani JE, Sandoval D, Saldías C, Crisosto N, Maliqueo M, Sir-Petermann T. Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. Steroids. 2018;130:15-21. 
  66. Lindholm A, Blomquist C, Bixo M, Dahlbom I, Hansson T, Sundström Poromaa I, Burén J. No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls. Hum Reprod. 2011;26:6:1478-1485.
  67. Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. 2019;20:9:2358.
  68. Hammarstedt A, Gogg S, Hedjazifar S, Nerstedt A, Smith U. Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity. Physiol Rev. 2018;98:1911-1941.
  69. Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues — the biology of pear shape. Biol Sex Differ. 2012;3:13. 
  70. Virtue S, Vidal-Puig A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol. 2008;6:e237.
  71. Zerradi M, Dereumetz J, Boulet MM, Tchernof A. Androgens, body fat distribution and adipogenesis. Curr Obes Rep. 2014;3:396-403. 
  72. Ribeiro VB, Kogure GS, Lopes IP, Silva RC, Pedroso DCC, Ferriani RA, Furtado CLM, Reis RMD. Association of measures of central fat accumulation indices with body fat distribution and metabolic, hormonal, and inflammatory parameters in women with polycystic ovary syndrome. Arch Endocrinol Metab. 2019;63:4:417-426. 
  73. Evans DJ, Barth JH, Burke CW. Body fat topography in women with androgen excess. Int J Obes. 1988;12:157-162. 
  74. Toscani M, Migliavacca R, Sisson de Castro JA, Spritzer PM. Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome. Metabolism. 2007;56:992-997. 
  75. Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol. 2008;108:272-280. 
  76. Tchernof A, Despres JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res. 2000;32:526-536. 
  77. Kempegowda P, Melson E, Manolopoulos KN, Arlt W, O’Reilly MW. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:2042018820934319.
  78. Satyaraddi A, Cherian KE, Kapoor N, Kunjummen AT, Kamath MS, Thomas N, Paul TV. Body composition, metabolic characteristics, and insulin resistance in obese and nonobese women with polycystic ovary syndrome. J Hum Reprod Sci. 2019;12:2:78-84. 
  79. McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, Winer D, Tolentino L, Choi O, Zhang H, Hui Yen Chng M, Engleman E. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol. 2014;34:12:2637-2643.
  80. de Zegher F, Lopez-Bermejo A, Ibáñez L. Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol Metab. 2009;20:418-423. 
  81. Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, McCarthy MI. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:3:999-1004.
  82. Dolfing JG, Stassen CM, van Haard PM, Wolffenbuttel BH, Schweitzer DH. Comparison of MRI-assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS. Hum Reprod. 2011;26:1495-1500.
  83. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042.
  84. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res. 2002;34:616-621. 
  85. Chazenbalk G, Singh P, Irge D, Shah A, Abbott DH, Dumesic DA. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013;78:920-926. 
  86. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26:883-896. 
  87. Alshammari G, Khan R, Brameld J, Amer S, Lomax MA. Gene expression of inflammatory markers in adipose tissue between obese women with polycystic ovary and normal obese women. Eur Rev Med Pharmacol Sci. 2017;21:1099-1105.
  88. Sam S. Differential effect of subcutaneous abdominal and visceral adipose tissue on cardiometabolic risk. Horm Mol Biol Clin Investig. 2018;33:1. 
  89. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia. 2000;43:1498-1506.
  90. Dumesic DA, Tulberg A, Leung KL, Fisch SC, Grogan TR, Abbott DH, Naik R, Chazenbalk GD. Accelerated subcutaneous abdominal stem cell adipogenesis predicts insulin sensitivity in normal-weight women with polycystic ovary syndrome. Fertil Steril. 2021$116:1:232-242. 
  91. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:618-637. 
  92. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG. 2006;113:1203-1209.
  93. Tosi F, Di Sarra D, Kaufman JM, Bonin C, Moretta R, Bonora E, Zanolin E, Moghetti P. Total body fat and central fat mass independently predict insulin resistance, but not hyperandrogenemia in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:2:661-669. 
  94. Borruel S, Fernández-Durán E, Alpañés M, Martí D, Alvarez-Blasco F, Luque-Ramírez M, Escobar-Morreale HF. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 2013;98:3:1254-1263.
  95. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2003;79:1358-1364.
  96. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-887. 
  97. Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab. 2010;95: 740-747. 
  98. Kuchenbecker WK, Groen H, Zijlstra TM, Bolster JH, Slart RH, van der Jagt EJ, Kobold AC, Wolffenbuttel BH, Land JA, Hoek A. The subcutaneous abdominal fat and not the intraabdominal fat compartment is associated with anovulation in women with obesity and infertility. J Clin Endocrinol Metab. 2010;95:5:2107-2112.
  99. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11-18. 
  100. Marcadenti A, de Abreu-Silva EO. Different adipose tissue depots: metabolic implications and effects of surgical removal. Endocrinol Nutr. 2015;62:458-464. 
  101. Xu X, De Pergola G, Eriksson PS, Fu L, Carlsson B, Yang S, Edén S, Björntorp P. Postreceptor events involved the up-regulation of beta-adrenergic receptor mediated lipolysis by testosterone in rat white adipocytes. Endocrinology. 1993;132:4:1651-1657.
  102. Holte J, Bergh T, Berne C, Berglund L, Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab. 1994;78:1052-1058.
  103. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG. beta-Cell function: a key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:310-315. 
  104. Malin SK, Kirwan JP, Sia CL, González F. Pancreatic β-cell dysfunction in polycystic ovary syndrome: role of hyperglycemia-induced nuclear factor-κB activation and systemic inflammation. Am J Physiol Endocrinol Metab. 2015;308:E770-777. 
  105. Zhang B, Wang J, Shen S, Liu J, Sun J, Gu T, Ye X, Zhu D, Bi Y. Association of excess androgens with glucose intolerance in women with polycystic ovary syndrome. Biomed Res Int. 2018;2018:6869705.
  106. Xu W, Morford J, Mauvais-Jarvis F. Emerging testosterone’s role in pancreatic β cell function and insulin secretion. J Endocrinol. 2019:JOE-18-0573.R1. 
  107. Horejsi R, Möller R, Rackl S, Giuliani A, Freytag U, Crailsheim K, Sudi K, Tafeit E. Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. Am J Phys Anthropol. 2004;124:3:275-281. 
  108. Yang J, Eliasson B, Smith U, Cushman SW, Sherman AS. The size of large adipose cells is a predictor of insulin resistance in first degree relatives of type 2 diabetic patients. Obesity (Silver Spring). 2012;20:5:932-938. 
  109. Alexiou E, Hatziagelaki E, Pergialiotis V, Chrelias C, Kassanos D, Siristatidis C, Kyrkou G, Kreatsa M, Trakakis E. Hyperandrogenemia in women with polycystic ovary syndrome: prevalence, characteristics and association with body mass index. Horm Mol Biol Clin Investig. 2017;29:3:105-111. 
  110. Holmäng A, Larsson BM, Brzezinska Z, Björntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol. 1992;262:E851-855. 
  111. Rincon J, Holmäng A, Wahlström EO, Lönnroth P, Björntorp P, Zierath JR, Wallberg-Henriksson H. Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Diabetes. 1996;45:5:615-621. 
  112. Allemand MC, Irving BA, Asmann YW, Klaus KA, Tatpati L, Coddington CC, Nair KS. Effect of testosterone on insulin stimulated IRS1 Ser phosphorylation in primary rat myotubes-a potential model for PCOS-related insulin resistance. PLoS One. 2009; 4:e4274.
  113. Jamnongjit M, Hammes SR. Ovarian steroids: the good, the bad, and the signals that raise them. Cell Cycle. 2006;5:11:1178-1183.
  114. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84:9:3110-3116.
  115. Futterweit W. Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Surv. 1999;54:403-413. 
  116. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol. 1993;264:E197-202. 
  117. Ciaraldi TP, Morales AJ, Hickman MG, Odom-Ford R, Olefsky JM, Yen SS. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab. 1997;82:1421-1425.
  118. Moghetti P, Tosi F. Insulin resistance and PCOS: chicken or egg? J Endocrinol Invest. 2021;44:233-244. 
  119. Rubin KH, Glintborg D, Nybo M, Abrahamsen B, Andersen M. Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102:3848-3857.
  120. O’Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993;76:5:1241-1247.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.